Friday, July 10, 2026

pharma · Not applicable, healthy volunteers · ulcerative pyoderma gangrenosum

InflaRx

InflaRx clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Jena, DE HQ
2007 Founded
52 Employees
EMA registrant Type
Company details
Status
Public
HQ
Jena, DE
Founded
2007
Employees
52
Programs
4
Drugs
20
Patents
0
Intelligence · Clinical Programs

InflaRx projects

4 ClinicalTrials.gov programs sponsored by InflaRx.

InflaRx has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. IFX-1-P3.4

    InflaRx GmbH

    ulcerative pyoderma gangrenosum

    phase 3 small molecule active

    1 trial
  2. INF904

    InflaRx GmbH

    Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)

    phase 2 small molecule active

    1 trial
  3. INF904-P1.2

    InflaRx GmbH

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial
  4. INF904-P1.3

    InflaRx GmbH

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does InflaRx have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.